Simulations Plus, Inc. (NASDAQ:SLP) declared a quarterly dividend on Wednesday, April 10th, Wall Street Journal reports. Investors of record on Wednesday, April 24th will be paid a dividend of 0.06 per share by the technology company on Wednesday, May 1st. This represents a $0.24 annualized dividend and a dividend yield of 1.07%. The ex-dividend date is Tuesday, April 23rd.
Simulations Plus has increased its dividend payment by an average of 6.3% per year over the last three years and has increased its dividend every year for the last 2 years. Simulations Plus has a dividend payout ratio of 60.0% meaning its dividend is sufficiently covered by earnings. Analysts expect Simulations Plus to earn $0.54 per share next year, which means the company should continue to be able to cover its $0.24 annual dividend with an expected future payout ratio of 44.4%.
NASDAQ SLP opened at $22.44 on Monday. The company has a market capitalization of $393.04 million, a price-to-earnings ratio of 44.88 and a beta of -0.50. Simulations Plus has a 52 week low of $16.26 and a 52 week high of $23.95.
Several equities research analysts have commented on the company. Zacks Investment Research upgraded Simulations Plus from a “sell” rating to a “hold” rating in a research note on Wednesday, March 20th. BidaskClub cut Simulations Plus from a “buy” rating to a “hold” rating in a research note on Thursday, April 11th. Finally, Taglich Brothers cut Simulations Plus from a “buy” rating to a “speculative buy” rating in a research note on Wednesday, January 16th.
In other news, insider Walter S. Woltosz sold 18,500 shares of the company’s stock in a transaction that occurred on Monday, January 28th. The stock was sold at an average price of $18.66, for a total transaction of $345,210.00. Following the sale, the insider now owns 5,250,912 shares in the company, valued at approximately $97,982,017.92. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director David L. Ralph sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $22.74, for a total value of $68,220.00. Following the sale, the director now owns 18,006 shares in the company, valued at approximately $409,456.44. The disclosure for this sale can be found here. Insiders sold a total of 58,500 shares of company stock worth $1,177,295 in the last 90 days. Company insiders own 31.57% of the company’s stock.
An institutional investor recently raised its position in Simulations Plus stock. Geode Capital Management LLC lifted its stake in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 6.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 128,181 shares of the technology company’s stock after purchasing an additional 7,794 shares during the period. Geode Capital Management LLC owned 0.73% of Simulations Plus worth $2,550,000 at the end of the most recent quarter. Institutional investors and hedge funds own 40.74% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/22/simulations-plus-inc-slp-plans-quarterly-dividend-of-0-06.html.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Further Reading: Market Capitalization and Individual Investors
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.